AARD - NASDAQ
Aardvark Therapeutics, Inc. Common Stock
$3.81
-4.5%Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
At a Glance
Live SnapshotAardvark Therapeutics, Inc. Common Stock Management Team
Dr. Tien-Li Lee M.D.
Chief Executive Officer, Secretary & Director
Compensation
$703,099
Mr. Nelson B. Sun M.B.A.
Chief Financial Officer
Dr. Manasi Sinha Jaiman M.D., M.P.H.
Chief Medical Officer
Compensation
$503,943
Dr. Bryan Jones Ph.D.
Chief Operating Officer
Compensation
$467,437
Dr. Zhenhuan Zheng Ph.D.
Chief Research Officer
Dr. Dvorit Samid Ph.D.
Executive Vice President of Medical Affairs
Mr. Tom Bicsak Ph.D.
Head of Regulatory Affairs & Quality
Dr. Andreas Niethammer M.D., Ph.D.
Head of Translational Medicine
Aardvark Therapeutics, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $13.87M and sold $78K worth of AARD shares, resulting in $13.79M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
10.0K
144.59K
0
0.00
+145K
+$145K
6-9 Months
33.8K
276.21K
1.2K
5.21K
+271K
+$271K
9-12 Months
1.2M
13.45M
17.2K
72.97K
+13.4M
+$13.38M
Top Buyers
Lee Tien-Li
Director, 10 Percent Owner, Officer: Chief Executive Officer
$6.53M
Sun Nelson
Officer: Chief Financial Officer
$2.46M
Jaiman Manasi
Officer: Chief Medical Officer
$1.43M
Jones Bryan
Officer: Chief Operating Officer
$1.38M
Tong Victor Edward Jr
Director
$689K
Top Sellers
Lee Tien-Li
Director, 10 Percent Owner, Officer: Chief Executive Officer
$78K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $13.79M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
AARD - Filing history and reports
No SEC filings available for AARD
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.